FTC Says It Can Place HSR Act Restrictions On Drug Cos.

Law360, New York (March 11, 2014, 7:59 PM EDT) -- The Federal Trade Commission said Monday it has the authority to issue reporting requirements that impact just the pharmaceutical industry, and asked a Washington, D.C., federal judge to rule in its favor in a dispute over patent licenses with the Pharmaceutical Research and Manufacturers of America.

The FTC said in a summary judgment motion that the FTC has the authority to require drug makers to report more exclusive patent licenses for antitrust approval under the Hart-Scott-Rodino Act.

“[PhRMA] asserts that Congress intended to prohibit the commission from...
To view the full article, register now.